Table 1.

Incidence of any and clinically significant hypertension in clinical trials of vascular endothelial growth factor signaling pathway (VSP) inhibitors^*

Agent	First author, year (reference)	Total No. of patients treated	Total incidence, %	Incidence of grade ≥ 3, %	Incidence of any grade hypertension in the comparator group, %
Aflibercept	Tew, 2007 (15)	162	46	18	NA
Axitinib†	Rugo, 2007 (16)	167	30	5	5
Bevacizumab‡	Hurwitz, 2004 (17)	790	22	11	8
Cediranib†	Hirte, 2008 (18)	49	72	33	NA
Motesanib	Sherman, 2008 (19)	93	56	25	NA
Pazopanib‡	Hutson, 2007 (20)	161	37	8	NA
Sorafenib†	Escudier, 2007 (21)	902	17	4	2
Sunitinib†	Motzer, 2007 (22)	735	24	8	1
Vandetanib	Arnold, 2007 (23)	106	21	2	9

^*For each agent, one of the larger studies with that drug and the reported incidence of hypertension by the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) is listed. For some agents, data from a randomized placebo-controlled trial are not yet available. Note the differences in reported rates, and grades cannot be accurately compared across trials because of differing clinical setting and the CTCAE versions used, but in every trial with a comparator arm, the incidence of hypertension is higher with the addition of the VSP inhibitor. NA = not applicable (no untreated comparator group).

^†Based on CTCAE version 3.0 (grade 3 hypertension is defined as “requiring more than one drug or more intensive therapy than previously”).

^‡Based on CTCAE version 2.0 (grade 3 hypertension is defined as “requiring initiation or increase medication”).